{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pfam:PF00531",
      "entity_text" : "death",
      "entity_type" : "family"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:10077130",
      "entity_text" : "vorapaxar",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "On top of standard antiplatelet therapy, vorapaxar reduces the risk of ischemic events or cardiovascular death in patients with stable coronary artery disease (CAD).",
  "reading_complete" : "2020-08-02T11:37:09Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T11:36:16Z",
  "trigger" : "reduces",
  "evidence" : [ "vorapaxar reduces the risk of ischemic events or cardiovascular death" ],
  "pmc_id" : "6697509",
  "score" : 0
}